Gritstone's Phase 2 cancer vaccine trial misses the mark, stock spirals down
02 Apr 2024
Phase 2Vaccine
Gritstone bio’s stock took a tumble in premarket trading Tuesday morning following mixed data from a Phase 2 study of its cancer vaccine, but it’s still moving ahead with a public offering of its stock and Phase 3 planning.
In a late Monday release, Gritstone touted the data as positive from the Phase 2 portion of its Phase 2/3 GRANITE trial of its neoantigen cancer vaccine in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). Progression-free survival favored Gritstone’s vaccine in an early trend, even though the dataset is “immature,” the company said in its presentation.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.